ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ALN-2232

A development code.

Its studies are mostly in Obesity, led by Alnylam Pharmaceuticals.

Furthest: phase 2, since Mar 6, 20261 company-led study, 1 open or runningNext primary completion: Apr 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals11 open or runningphase 2since Mar 6, 2026Mar 6, 2026Apr 28, 2027phase 2 · NCT07463846

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2026First study: phase 2 study in ObesityFirst studyNCT07463846 · 156 planned · Canada

Ahead

  1. Apr 28, 2027Primary completion: phase 2 study in ObesityNCT07463846

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07463846Obesity · Canada2RecruitingApr 28, 2027156

How it is read

Names in the registry

  • “ALN-2232”, 1 entry

Codes read as this program: ALN2232.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.